COVID-19

Pfizer sends data to FDA for vaccines for kids

If approved, the Pfizer vaccine could become available to children ages 5 to 11 as soon as October.

On Tuesday, Pfizer-BioNTech submitted its COVID-19 vaccine trial data to the Food and Drug Administration. That brings the vaccine one step closer to being available for children.

The pharmaceutical giant has been trialing the vaccine with people age 5 to 11 in hopes of expanding its availability. The company has said the two-dose regimen has been “well-tolerated” with a “robust” antibody response among the younger age group.

The FDA will spend the next few weeks analyzing the data. Pfizer-BioNTech will then formally apply for emergency use authorization, which would then take more time to approve. Dr. Anthony Fauci, who advises the White House’s COVID-19 response, has said we could start inoculating children by the end of October.

The fall surge of the coronavirus has been pushed ever higher by unvaccinated people contracting the highly transmissible Delta strain. Since children under 12 can’t be vaccinated, that group has been especially hard hit.

[NBC News, MLive]